<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        133-276-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        KEPPRA 500MG F.C.TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVETIRACETAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        242.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="U.C.B." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            U.C.B.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keppra contains the active ingredient levetiracetam. It belongs to antiepileptic medicines, which are used to treat fits (<em>seizures</em>) in epilepsy.</p><p>On its own, Keppra is used to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; partial onset seizure with or without secondary generalisation (the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain) - in adults and adolescents from 16 years of age with newly diagnosed epilepsy</p><p>As an add-on to other antiepileptic medicines, Keppra is used to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age with epilepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Don&rsquo;t take </strong><strong>Keppra</strong><strong> </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> (<em>hypersensitive</em>) to levetiracetam, other pyrrolidone derivatives, or any other ingredients of Keppra (listed in Section 6)</p><p>If you think any of these apply to you,<strong> don&rsquo;t take Keppra</strong> until you have checked with your doctor.</p><p><strong>Take special care with Keppra</strong><strong> </strong></p><p>Before you take Keppra your doctor needs to know:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>kidney problems or </strong><strong>severe liver disease</strong>, your doctor may need to adjust your dose of Keppra</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>pregnant or breastfeeding</strong>, think you may be pregnant or are planning to have a baby (see <em>Pregnancy and breast-feeding</em> later in section 2)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>taking any other medicines</strong> (see <em>Other medicines and Keppra</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you <strong>are over 65</strong></p><p><strong>Check with your doctor </strong>if you think any of these may apply to you<strong>. </strong>Your doctor will decide whether Keppra is suitable for you.</p><p><strong>Keppra film-coated tablets are not recommended for children under 6 years.</strong></p><p><strong>Keppra oral solution</strong> is the preferred formulation for use in infants and children <strong>under the age of 6 years.</strong></p><p><strong>Keppra</strong> <strong>is not indicated in children and adolescents below 16 years on its own</strong> (as monotherapy) (see <em>What </em><em>Keppra</em><em> is and what it is used for</em> in Section 1).</p><p><strong>While you are taking</strong><strong> Keppra</strong></p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you notice any slow down in the growth or unexpected puberty development of your child, <strong>contact your doctor</strong>.</p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A small number of people being treated with anti-epileptics such as Keppra have had <strong>thoughts of harming or killing themselves</strong>. If at any time you have these thoughts, <strong>immediately contact your doctor</strong>.</p><p><strong>Conditions you need to look out for</strong></p><p>Keppra can make some existing conditions worse, or cause serious side effects such as <strong>severe allergic reactions,</strong><strong> serious skin reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</strong>, <strong>sudden decrease of kidney function</strong><strong>, </strong><strong>encephalopathy </strong>(degenerative disease of the brain),<strong> depression or </strong><strong>suicidal thoughts</strong>. You must look out for certain symptoms while you are taking Keppra, to reduce the risk of any problems. See &lsquo;<em>Conditions you need to look out for&rsquo;&nbsp; </em>in Section 4.&nbsp;</p><p><strong>Other medicines and Keppra</strong><strong> </strong></p><p><strong>Tell your doctor or pharmacist if you&#39;re taking any other medicines</strong>, if you&rsquo;ve taken any recently, or if you start taking new ones. This includes medicines bought without a prescription.</p><p>Don&#39;t take <strong>macrogol</strong> (a drug used as <strong>laxative</strong>) for one hour before and one hour after taking Keppra &nbsp;as this may results in a loss of its effect.</p><p>You will be closely monitored if you are taking Keppra with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; methotrexate (used to treat certain types of <strong>cancer</strong>)</p><p>Some other medicines may affect how Keppra works, or make it more likely that you&rsquo;ll have side effects. Keppra can also affect how some other medicines work. These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; probenecid (used to treat <strong>gout</strong>)</p><p><strong>Tell your doctor or pharmacist</strong> if you are taking any of these.</p><p><strong>Pregnancy and breast-feeding</strong></p><p><strong>Keppra is not recommended for use during pregnancy.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell your doctor if you are pregnant</strong> or planning to become pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use a <strong>reliable method of contraception</strong> while you&rsquo;re taking Keppra, to prevent pregnancy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you do become pregnant during treatment</strong> with Keppra, tell your doctor.</p><p>Keppra can be used during pregnancy, only if after careful assessment it is considered necessary by your doctor. <strong>You should not stop your treatment without discussing this with your doctor</strong>. A risk of birth defects for your unborn child cannot be completely excluded. Keppra has shown unwanted reproductive effects in animal studies.</p><p><strong>Breast-feeding is not recommended</strong> during treatment with Keppra. The ingredients can pass into your breast milk. Talk to your doctor about this.</p><p><strong>Driving and using machines</strong></p><p><strong>Keppra can make you feel drowsy or sleepy</strong> and have other side effects that make you less alert. This is more likely at the beginning of treatment or after an increase in the dose.</p><p><strong>Don&rsquo;t drive or use machines</strong> unless you are sure you&rsquo;re not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much to take </strong></p><p><strong>Always take Keppra exactly as your doctor has told you to.</strong> Check with your doctor or pharmacist if you&#39;re not sure.</p><p>Take the number of tablets following your doctor&rsquo;s instructions.</p><p>Keppra must be taken <strong>twice a day</strong>, once in the morning and once in the evening, at about the same time each day.</p><p><strong>Monotherapy</strong></p><p><strong><u>Monotherapy in adults and adolescents (from 16 years of age)</u></strong></p><p><strong>Keppra </strong><strong>film-coated tablets </strong></p><p>When you will first start taking Keppra, your doctor will prescribe you a <strong>lower dose</strong> during first<br />2 weeks of treatment, before giving you the lowest general dose.</p><p><strong>The usual starting dose</strong> of Keppra is <strong>250 mg twice daily</strong>. Your doctor will increase your dose to <strong>500 mg</strong>, <strong>twice daily</strong> after two weeks of treatment.</p><p>Your doctor may decide to further increase your dose to a maximum of <strong>1500 mg, twice daily</strong> - depending on how you respond to the medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Add-on therapy</strong></p><p><strong><u>Add-on therapy in adults and adolescents (12 to 17 years) weighing 50 kg or more</u></strong></p><p><strong><u>Keppra film-coated tablets </u></strong></p><p><strong>The usual starting dose</strong> of Keppra is <strong>500 mg twice daily</strong>. Your doctor may decide to gradually increase your dose to a maximum of <strong>1500 mg, twice daily</strong> - depending on how you respond to the medicine.</p><p><strong>Patients with kidney problems </strong></p><p>Your doctor will decide on the correct dose of Keppra for you/your child depending on kidney function and the body weight.</p><p><strong>How to take</strong></p><p><strong>Film-coated tablets</strong></p><p>Swallow Keppra tablet(s) with a sufficient quantity of liquid (for example a glass of water). You can take Keppra with or without food. After oral administration the bitter taste of levetiracetam may be experienced.</p><p>&nbsp;</p><p><strong>If you forget to take Keppra</strong></p><p><strong>Don&#39;t take an extra dose to make up for a missed dose</strong>. <strong>Contact your doctor if you have missed one or more doses.</strong></p><p><strong>If you take too much Keppra</strong></p><p>If you take<em> </em>more Keppra than you should you may be <strong>more likely to feel drowsy, agitated or have other side effects such as decrease of alertness, aggression, shallow breathing and loss of consciousness (coma).</strong></p><p><strong>Don&#39;t delay.</strong> <strong>Contact your doctor or your nearest hospital emergency department immediately</strong>. If possible, show them the Keppra pack.</p><p><strong>Don&rsquo;t stop </strong><strong>Keppra without advice</strong></p><p><strong>Take Keppra for as long as your doctor recommends</strong>. Don&rsquo;t stop unless your doctor advises you to. If you are suffering from epilepsy abruptly stopping your medicine may increase your fits (<em>seizures</em>).</p><p>If stopping treatment, Keppra should be discontinued gradually. Your doctor will instruct you about the gradual withdrawal of Keppra.</p><p>Ask your doctor or pharmacist if you have any questions on the use of this product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Keppra can cause side effects, but not everybody gets them.</p><p><strong>Conditions you need to look out for</strong></p><p><strong>Severe allergic reactions.</strong> These are rare in people taking Keppra.<strong> </strong>Signs include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; raised and itchy rash (hives)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; swelling, sometimes of the face or mouth (<em>angioedema</em>), causing difficulty in breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; collapse or loss of consciousness</p><p><strong>Serious skin reactions.</strong> These are rare in people taking Keppra.<strong> </strong>Signs include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, which may blister, and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge - <em>erythema multiforme)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (<em>Stevens Johnson Syndrome)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; extensive peeling of the skin on much of the body surface <em>&ndash; (toxic epidermal necrolysis)</em></p><p><strong>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</strong>. These are rare in people taking Keppra.<strong> </strong>Signs include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; flu-like symptoms and a rash on the face followed by an extended rash with a high temperature</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; enlarged lymph nodes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell</p><p>(<em>eosinophilia</em>)</p><p><strong>Sudden decrease of kidney function. </strong>This is rare in people taking Keppra.<strong> </strong>Signs include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; low urine volume</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; tiredness, nausea, vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; swelling in the legs, ankles or feet</p><p><strong>Encephalopathy </strong>(degenerative disease of the brain). This is rare (and may occur at the beginning of the treatment) in people taking Keppra.<strong> </strong>Signs include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; serious mental changes or signs of confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling drowsy (somnolence)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; loss of memory (amnesia), memory impairment (forgetfulness)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; abnormal behaviour</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; other neurological signs including involuntary or uncontrolled movements</p><p><strong>Depression. </strong>This is common in people taking Keppra.</p><p><strong>Suicidal thoughts.</strong> These are uncommon in people taking Keppra.<strong> </strong>&nbsp;</p><p><strong>Get medical help immediately</strong> if you get these symptoms.</p><p>Very common side effects</p><p>These may affect <strong>more than 1 in 10</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the nasopharynx (<em>nasopharyngitis</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling drowsy (<em>somnolence</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p><strong>Common side effects</strong></p><p>These may affect <strong>up to 1 in 10 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite (<em>anorexia</em>) - especially if you take another drug called topiramate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; depression, hostility or aggression, anxiety, difficulty in sleeping, nervousness or irritability</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; fits (<em>seizures</em>), balance disorder, dizziness, abnormal drowsiness (<em>lethargy</em>), tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; spinning sensation (<em>vertigo</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain, diarrhoea, indigestion, vomiting, feeling sick (<em>nausea</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak or lack of energy</p><p><strong>Uncommon side effects</strong></p><p>These may affect <strong>up to 1 in 100</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; decreased or increased weight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; suicide attempt and suicidal ideation, mental disorder, abnormal behaviour, seeing or hearing things that are not really there (hallucination), anger, confusion, panic attack, emotional instability/mood swings, agitation;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; loss of memory, memory impairment (forgetfulness), abnormal coordination or loss of coordinated bodily movements, tingling or numbness of the hands or feet, disturbance in attention (loss of concentration)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; double vision, blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; unusual hair loss or thinning, eczema, itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness, muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; injury</p><p>Uncommon side effects that may show up in blood tests:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; decrease in number of blood platelets - cells that help blood to clot (<em>thrombocytopenia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of white blood cells (<em>leucopenia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; elevated/abnormal values in a liver function test</p><p>&nbsp;</p><p>Rare side effects</p><p>These may affect <strong>up to 1 in 1,000</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (see &lsquo;Severe allergic reactions&rsquo; earlier in Section 4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; drug-induced hypersensitivity reaction that includes fever, rash, and blood abnormalities (see Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) earlier in Section 4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; suicide, personality disorders (behavioural problems), abnormal thinking</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; uncontrollable muscle spasms affecting the eyes, head, neck and body, uncontrollable movements, hyperactivity (unusually overactive)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; liver failure, inflammation of the liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; erythema multiforme, Stevens Johnson Syndrome, toxic epidermal necrolysis (see &lsquo;Serious skin reactions&rsquo; earlier in Section 4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; acute kidney injury (see &lsquo;Sudden decrease of kidney function&rsquo; earlier in Section 4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; limp or difficulty walking.</p><p>Rare side effects that may show up in blood tests:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; decrease in number of all types blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; decrease in sodium in the blood</p><p><strong>Tell your doctor or pharmacist</strong> if any of the side effects listed becomes <strong>severe or troublesome</strong>, or if you notice any side effects not listed in this leaflet.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222, Ext: 2317-2356-2340</li><li>Reporting Hotline: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc<u> </u></li></ul><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: <u>s</u>audi.safety@gsk.com<u>&nbsp; </u></li><li>Website: https://gskpro.com/en-sa/<u> </u></li></ul><p>P.O. Box 55850, Jeddah 21544, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Keppra after the expiry date which is stated on the pack after &lsquo;Exp&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store Keppra at below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor tells you to stop taking Keppra, it is important to return any remnants which are left over to your pharmacist.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance(s) is levetiracetam.</p><p>Keppra 250 mg: Each tablet contains 250 mg of levetiracetam.</p><p>Keppra 500 mg: Each tablet contains 500 mg of levetiracetam.</p><p>Keppra 1000 mg: Each tablet contains 1000 mg of levetiracetam.</p><p>&nbsp;</p><p>The other ingredient(s) are:</p><p><strong>Tablet core: </strong>croscarmellose sodium, macrogol 6000, silica colloidal anhydrous, magnesium stearate.</p><p><strong>Film-coating:</strong></p><p><strong>KEPPRA 250 mg tablet</strong></p><p>Opadry 85F20694: Polyvinyl alcohol-part.hydrolyzed, Titanium dioxide (E171), Macrogol 3350, Talc, Indigo carmine aluminium lake (E132)</p><p><strong>KEPPRA 500 mg tablet</strong></p><p>Opadry 85F32004: Polyvinyl alcohol-part.hydrolyzed, Titanium dioxide (E171), Macrogol 3350, Talc, Iron oxide (E172)</p><p><strong>KEPPRA 1000 mg tablet</strong></p><p>Opadry 85F18422: Polyvinyl alcohol-part.hydrolyzed, Titanium dioxide (E171), Macrogol 3350, Talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Keppra, 250 mg, film-coated tablets
Blue, oblong film-coated tablet scored and debossed with the code ucb and 250 on one side.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
‎
Keppra, 500 mg, film-coated tablets
Yellow, oblong film-coated tablet scored and debossed with the code ucb and 500 on one side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

Keppra, 1000 mg, film-coated tablets
White, oblong film-coated tablet scored and debossed with the code ucb and 1000 on one side. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

The pack: aluminium/PVC blisters placed into cardboard boxes containing 10, 20, 30, 50, 60, 100 and 200 (2 x 100) film-‎coated tablets.

Not all pack sizes may be marketed.

Keppra is a registered trademark of the GlaxoSmithKline group of companies 
© 2020 GlaxoSmithKline, all rights reserved.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA.</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia.</p><p>*member of GlaxoSmithKline group of companies.</p><p>&nbsp;</p><p><strong>Manufactured by</strong></p><p>UCB PHARMA SA, BRAINE-L&rsquo;ALLEUD. BELGIUM</p><p><strong>Packed by:</strong></p><p>Glaxo Saudi Arabia Ltd*, Jeddah, KSA</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com</li><li>Website: https://gskpro.com/en-sa/<u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version number: NCDS09
Date of issue: 17 September 2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي كيبرا على المكوّن الفعَّال ليفيتيراسيتام&rlm;‫. وهو ينتمي إلى الأدوية المضادة للصرع، والتي تستخدم لعلاج نوبات <em>(تشنجات)</em> الصرع.</p><p>ويُستخدم كيبرا بمفرده لعلاج:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; النوبات ذات البداية الجزئية مع أو بدون تعميم ثانوي (شكل الصرع الذي تؤثر فيه النوبات في البداية على جانب واحد من الدماغ، ولكن يمكن أن يمتد بعد ذلك إلى مناطق أكبر على جانبي الدماغ) - لدى البالغين والمراهقين من عمر 16 عامًا المشخصين حديثًا بالإصابة بالصرع</p><p>&nbsp;</p><p>وكعلاج إضافي مع أدوية أخرى مضادة للصرع، يُستخدم كيبرا لعلاج:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; النوبات ذات البداية الجزئية مع أو بدون تعميم لدى البالغين والمراهقين والأطفال والرضع من شهر واحد من العمر المصابين بالصرع</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; النوبات الارتجاجية العضلية (اهتزازات قصيرة لعضلة أو مجموعة من العضلات) لدى البالغين والمراهقين من عمر 12 عامًا المصابين بصرع الصغار الارتجاجي العضلي</p><p>النوبات التورية الارتجاجية المعممة المبدئية (نوبات شديدة تتضمن فقدان الوعي) لدى البالغين والمراهقين من عمر 12 عامًا المصابين بصرع عام غير معروف السبب (نوع الصرع الذي يُعتقد أنه يرجع لسبب وراثي)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول كيبرا </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; في حالة وجود <strong>حساسية</strong> <em>(فرط الحساسية)</em> لليفيتيراسيتام&rlm;‫، أو مشتقات بيروليدون الأخرى أو أي من المكوّنات الأخرى لدواء كيبرا (المدرجة في القسم 6)</p><p>إذا كنت تعتقد أن أي من هذه الحالات ينطبق عليك، <strong>فلا تتناول كيبرا</strong> إلى أن تستشر طبيبك.</p><p><strong>ينبغي توخي الحذر عند استخدام كيبرا </strong></p><p>قبل تناول كيبرا، يحتاج طبيبك إلى معرفة ما يلي:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>مشاكل في الكلى أو مرض كبدي خطير</strong>، قد يحتاج طبيبك إلى تعديل الجرعة الموصوفة لك من كيبرا</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ <strong>حاملاً أو ترضعين طفلك رضاعة طبيعية</strong> أو تظنين أنكِ حامل أو تنوين الإنجاب (انظري <em>الحمل والرضاعة الطبيعية</em> لاحقًا في القسم &rlm;‫2)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت <strong>تتناول أية أدوية أخرى</strong> (انظر <em>الأدوية الأخرى وكيبرا</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عمرك <strong>يزيد عن </strong><strong>65</strong><strong> عامًا</strong></p><p><strong>استشر الطبيب</strong> إذا كنت تعتقد أن أي من هذه الحالات تنطبق عليك. سوف يقرر طبيبك ما إذا كان كيبرا مناسبًا لك أم لا.</p><p><strong>لا يوصى باستخدام أقراص كيبرا المغلَّفة مع الأطفال الذين تقل أعمارهم عن </strong><strong>6</strong><strong> سنوات.</strong></p><p><strong>محلول كيبرا للتناول عن طريق الفم</strong> هو الشكل الصيدلي الأنسب للاستخدام مع الرضع والأطفال <strong>دون سن </strong><strong>6</strong><strong> سنوات</strong>.</p><p><strong>لا يوصف كيبرا لعلاج الأطفال والمراهقين الأقل من </strong><strong>16</strong><strong> عامًا بمفرده</strong> (كعلاج أحادي) (انظر <em>معلومات عن كيبرا ودواعي استعماله</em> في القسم 1).</p><p><strong>أثناء تناول كيبرا</strong></p><p>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت أي تأخر في نمو طفلك أو لاحظت ظهور أعراض بلوغ غير متوقعة، <strong>اتصل بطبيبك.</strong></p><p><strong>&minus;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>وهناك عدد قليل من الأشخاص الذين يعالجون بمضادات الصرع، مثل كيبرا، <strong>كان لديهم أفكار لإيذاء أو قتل أنفسهم.</strong> إذا راودتك هذه الأفكار في أي وقت، <strong>اتصل بطبيبك على الفور. </strong></p><p><strong>حالات ينبغي الانتباه لها</strong></p><p>يمكن أن يؤدي كيبرا إلى تفاقم بعض الحالات الموجودة بالفعل، أو يسبب آثارًا جانبية خطيرة، مثل <strong>تفاعلات الحساسية الشديدة، تفاعلات الجلد الخطيرة، التفاعلات الدوائية مع فرط الحمضات والأعراض الجهازية </strong><strong>(DRESS)</strong><strong>، الانخفاض المفاجئ في وظائف الكلى، الاعتلال الدماغي</strong> (مرض تنكسى في الدماغ)، <strong>الاكتئاب أو الأفكار الانتحارية.</strong> لذا، يتعين عليك الانتباه لبعض الأعراض المعينة أثناء تناول كيبرا للحد من مخاطر حدوث أية مشكلات. انظر <em>&quot;حالات ينبغي الانتباه لها&quot;</em> في القسم 4.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>الأدوية الأخرى وكيبرا </strong></p><p><strong>أخبر طبيبك أو الصيدلي إذا كنت تتناول أدوية أخرى في الوقت الحالي،</strong> أو تناولت أية أدوية مؤخرًا أو إذا بدأت تناول أدوية جديدة. ويشمل ذلك الأدوية التي يتم شراؤها دون وصفة طبية.</p><p>لا تتناول <strong>ماكروجول</strong> (دواء يُستخدم <strong>كملين</strong>) لمدة ساعة قبل تناول كيبرا وساعة بعد تناوله لأن هذا الدواء قد يؤدي إلى فقدان تأثيره.</p><p>سيتم مراقبتك عن كثب إذا كنت تتناول كيبرا مع:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; الميثوتريكسات (يُستخدم لعلاج أنواع معينة من <strong>السرطان</strong>)</p><p>قد تؤثر بعض الأدوية الأخرى على فاعلية دواء كيبرا أو يمكن أن تزيد من احتمالية التعرض للآثار الجانبية. يمكن أن يؤثر كيبرا على فعالية بعض الأدوية الأخرى. وتشمل تلك الأدوية:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; بروبينسيد (يُستخدم لعلاج <strong>النقرس</strong>&rlm;‫)</p><p><strong>ينبغي إخبار طبيبك أو الصيدلي</strong> إذا كنت تتناول أي من هذه الأدوية.</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p><strong>لا يُوصى بتناول كيبرا أثناء فترة الحمل.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أخبري الطبيب إذا كنتِ حاملًا</strong> أو تنوين الحمل.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدمي <strong>طريقة موثوقة لمنع الحمل</strong> أثناء تناول كيبرا لمنع حدوث الحمل.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا أصبحتِ حاملًا أثناء العلاج</strong> باستخدام كيبرا، أخبري طبيبك.</p><p>يمكن استخدام &nbsp;كيبرا أثناء فترة الحمل ، فقط إذا كان التقييم ضروريًا من قبل طبيبك. يجب عليك عدم التوقف عن علاجك دون مناقشة هذا الأمر مع طبيبك. لا يمكن استبعاد خطر حدوث عيوب خلقية تمامًا للجنين.<br />أظهر كيبرا آثارًا غير مرغوب فيها تتعلق بالإنجاب في الدراسات التي تم إجراؤها على الحيوانات.</p><p><strong>لا يُنصح بالرضاعة الطبيعية </strong>أثناء العلاج بكيبرا. حيث يمكن أن تنتقل المكونات إلى لبن الأم. تحدثي إلى طبيبِك في هذا الشأن.</p><p><strong>القيادة واستخدام الآلات</strong></p><p><strong>قد يجعلك كيبرا تشعر بالخمول أو النعاس</strong> وغيره من الأعراض الجانبية التي تجعلك أقل يقظة. وعلى الأرجح أن يحدث ذلك في بداية العلاج أو بعد زيادة الجرعة.</p><p><strong>ينبغي عدم القيادة أو استخدام الآلات</strong> إلا في حالة التأكد من عدم التأثُر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>مقدار الجرعة </strong></p><p><strong>ينبغي تناول كيبرا دائمًا وفقًا للجرعة التي حددها طبيبك.</strong> استشر الطبيب أو الصيدلي في حالة الشك بشأن طريقة استعماله على الوجه الصحيح.</p><p>تناول المحلول عن طريق الفم وفقًا لتعليمات طبيبك.</p><p>يجب تناول كيبرا <strong>مرتين في اليوم</strong>، مرة في الصباح ومرة في المساء، في نفس الوقت تقريبًا كل يوم.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>العلاج الأحادي</strong></p><p><strong><u>العلاج الأحادي في البالغين والمراهقين (من عمر </u></strong><strong><u>16</u></strong><strong><u> عامًا)</u></strong></p><p><strong>أقراص كيبرا المغلَّفة</strong></p><p>عند بدء تناول أقراص كيبرا المغلفة، سيصف لك الطبيب <strong>جرعة أقل</strong> خلال أول أسبوعين من العلاج، قبل إعطائك أدنى جرعة عامة.</p><p><strong>الجرعة المعتادة</strong> من أقراص كيبرا المغلَّفة هي <strong>250</strong><strong> ملجم مرتين في اليوم.</strong> سيقوم طبيبك بزيادة الجرعة إلى <strong>500</strong><strong> ملجم، مرتين يوميًا</strong> بعد أسبوعين من العلاج.</p><p>قد يقرر طبيبك زيادة الجرعة إلى <strong>1500</strong><strong> ملجم مرتين يوميًا</strong> - حسب استجابتك للدواء.</p><p>&nbsp;</p><p><strong>العلاج الإضافي</strong></p><p><strong><u>العلاج الإضافي في البالغين والمراهقين (من عمر </u></strong><strong><u>12</u></strong><strong><u> إلى </u></strong><strong><u>17</u></strong><strong><u> عامًا) الذين تزن أجسامهم </u></strong><strong><u>50</u></strong><strong><u> كجم أو أكثر</u></strong></p><p><strong><u>أقراص كيبرا المغلَّفة </u></strong></p><p><strong>الجرعة المعتادة</strong> من كيبرا هي <strong>500</strong><strong> ملجم مرتين في اليوم.</strong> قد يقرر طبيبك زيادة الجرعة تدريجيًا إلى <strong>1500</strong><strong> ملجم مرتين يوميًا</strong> - حسب استجابتك للدواء.</p><p><strong>&nbsp;</strong><strong><u>العلاج الإضافي للأطفال في عمر </u></strong><strong><u>6</u></strong><strong><u> أشهر وأكثر</u></strong></p><p><strong>محلول كيبرا للتناول عن طريق الفم</strong> هو الشكل الصيدلي الأنسب للاستخدام مع الرضع والأطفال <strong>دون سن </strong><strong>6</strong><strong> سنوات.</strong></p><p><strong>المرضى المصابون بمشكلات الكُلى </strong></p><p>سوف يقرر طبيبك الجرعة الصحيحة من كيبرا لك/لطفلك حسب وظائف الكلى ووزن الجسم.</p><p><strong>كيفية تناول الجرعة</strong></p><p><strong>أقراص كيبرا المغلَّفة</strong></p><p>ابتلع قرص/أقراص كيبرا المغلَّفة مع كمية كافية من السوائل (على سبيل المثال كوب من الماء). يمكنك تناول أقراص كيبرا المغلَّفة مع الطعام أو بدونه. بعد تناول كيبرا عن طريق الفم قد تصادف طعماً مراً.</p><p><strong>في حالة نسيان تناول كيبرا</strong></p><p><strong>لا تتناول جرعة إضافية لتعويض الجرعة التي فاتتك. اتصل بطبيبك إذا فاتتك جرعة أو أكثر.</strong></p><p><strong>في حالة تناول كمية أكبر من اللازم من كيبرا</strong></p><p>إذا تناولت جرعة كيبرا أكثر من اللازم، فمن المحتمل <strong>أن تشعر بالنعاس أو الهياج&rlm;</strong>‫<strong> أو يكون لديك آثار جانبية أخرى، مثل قلة اليقظة والعدوانية وضيق التنفس وفقدان الوعي (غيبوبة).</strong></p><p><strong>لا تتأخر. اتصل بالطبيب أو توجّه لقسم الطوارئ بأقرب مستشفى على الفور.</strong> ويُفضل أن تريهم عبوة كيبرا إن أمكن.</p><p><strong>لا توقف العلاج بكيبرا دون استشارة المختص</strong></p><p><strong>تناول كيبرا للمدة التي أوصى بها الطبيب.</strong> ويجب عدم وقف الدواء إلا إذا أوصى الطبيب بذلك. إذا كنت تعاني من الصرع، فإن وقف الدواء بشكل مفاجئ قد يزيد من النوبات <em>(التشنجات)</em>.</p><p>في حالة وقف العلاج، ينبغي وقف كيبرا تدريجيًا. سيقوم طبيبك بإرشادك بشأن سحب دواء كيبرا تدريجيًا.</p><p>استشر الطبيب أو الصيدلي إذا كانت لديك أي أسئلة إضافية حول استخدامات هذا المنتج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال في جميع الأدوية، يمكن أن يتسبب كيبرا في حدوث بعض الآثار الجانبية، ولكن ليس بالضرورة أن يصاب جميع الأشخاص بهذه الآثار.</p><p><strong>حالات ينبغي الانتباه لها</strong></p><p><strong>تفاعلات الحساسية الشديدة.</strong> هذه التفاعلات نادرة في حالة الأشخاص الذين يتناولون كيبرا. وتشمل العلامات:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي بارز وحاك (شرى)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تورم في بعض الأحيان للوجه والفم <em>(وذمة وعائية)</em>، مما ينتج عنه صعوبة في التنفس</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء أو فقدان الوعي</p><p><strong>تفاعلات البشرة الخطيرة.</strong> هذه التفاعلات نادرة في حالة الأشخاص الذين يتناولون كيبرا. وتشمل العلامات:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، والذي قد يتقرّح ويشبه الأجزاء الناتئة الصغيرة (بقع سوداء متمركزة تحيط بها مساحة شاحبة، مع وجود حلقة داكنة حول الأطراف - <em>حمامى متعددة الأشكال</em>)</p><p><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </em>طفح واسع الانتشار مصحوب بتقرّح وتقشر في الجلد، خاصةً حول الفم والأنف والعيون والأعضاء التناسلية <em>(متلازمة ستيفنز جونسون)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; تقشر واسع للجلد على مساحة كبيرة من سطح الجسم <em>(تقشر الأنسجة المتموتة البشروية التسممي)</em></p><p>&nbsp;</p><p><strong>التفاعلات الدوائية مع فرط الحمضات والأعراض الجهازية </strong><strong>(DRESS)</strong><strong>.</strong> هذه التفاعلات نادرة في حالة الأشخاص الذين يتناولون كيبرا. وتشمل العلامات:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; أعراض تشبه أعراض الإنفلونزا وطفح على الوجه يتبعه طفح جلدي متزايد مع ارتفاع في درجة الحرارة</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الغدد الليمفاوية</p><p><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </em>زيادة مستويات إنزيمات الكبد تظهر في اختبارات الدم وزيادة في نوع خلايا الدم البيضاء <em>(فرط الحمضات) </em></p><p>&nbsp;</p><p><strong>التراجع المفاجئ في وظائف الكلى.</strong> وهذا نادر الحدوث لدى الأشخاص الذين يتناولون كيبرا. وتشمل العلامات:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض كمية البول</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; التعب والغثيان والقيء</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الساقين أو الكاحلين أو القدمين</p><p>&nbsp;</p><p><strong>اعتلال الدماغ</strong> (مرض تنكسي في الدماغ). وهذا نادر الحدوث (وقد يحدث في بداية العلاج) لدى الأشخاص الذين يتناولون كيبرا.<br />وتشمل العلامات:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات نفسية خطيرة أو علامات الارتباك</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس (الرغبة في النوم)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة، ضعف الذاكرة (النسيان)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; السلوك غير الطبيعي</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; علامات عصبية أخرى، تشمل الحركات اللاإرادية أو التي لا يمكن التحكم فيها</p><p><strong>الاكتئاب&rlm;</strong>‫<strong>.</strong> وهذا أمر شائع الحدوث لدى الأشخاص الذين يتناولون كيبرا.</p><p><strong>أفكار انتحارية.</strong> وهي غير شائعة لدى المرضى الذين يتناولون كيبرا.&nbsp;</p><p><strong>احصل على مساعدة طبية على الفور</strong> إذا أصابتك هذه الأعراض.</p><p>الآثار الجانبية الشائعة جدًا</p><p>يمكن أن تصيب تلك الآثار <strong>أكثر من شخص واحد بين كل </strong><strong>10</strong><strong> أشخاص: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البلعوم الأنفي</p><p><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </em>الشعور بالنعاس <em>(الرغبة في النوم)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p><strong>الآثار الجانبية الشائعة</strong></p><p>قد تصيب <strong>حتى</strong> <strong>شخص واحد من كل </strong><strong>10</strong><strong> أشخاص:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية - خاصةً إذا كنت تتناول دواءً آخر يسمى توبيراميت</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب أو العداء أو العدوانية أو القلق أو صعوبة في النوم أو العصبية أو التهيج</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; النوبات <em>(التشنجات)</em> اضطراب في التوازن، دوخة، نعاس غير طبيعي <em>(خمول)</em>، رعاش</p><p><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </em>الإحساس بالدوار <em>(الدوار)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </em>ألم المعدة، الإسهال، عسر الهضم، التقيؤ، الشعور بالتوعك <em>(الغثيان)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف أو فقدان الطاقة</p><p><strong>الآثار الجانبية غير الشائعة</strong></p><p>قد تصيب <strong>حتى</strong> <strong>شخص واحد بين كل </strong><strong>100</strong><strong> شخص:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة أو نقصان في الوزن</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; محاولة الانتحار، التفكير الانتحاري، الاضطراب النفسي، السلوك غير الطبيعي، رؤية أو سماع أشياء غير موجودة (هلوسة)، الغضب، الارتباك، نوبات الهلع، عدم الاستقرار العاطفي/تقلب المزاج، الهياج؛</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة أو ضعف الذاكرة (النسيان) أو التنسيق غير الطبيعي أو فقدان الحركات الجسدية المتناسقة أو وخز أو تخدر في اليدين أو القدمين أو اضطراب في الانتباه (فقدان التركيز)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; ازدواج الرؤية، عدم وضوح الرؤية</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; سقوط الشعر، ترقق الشعر، الأكزيما، الحكة غير المعتادة</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات، آلام العضلات</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; الإصابات</p><p>&nbsp;</p><p>من بين الآثار الجانبية غير الشائعة التي تظهرها فحوصات الدم:</p><p><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp; </em>نقص في عدد الصفائح الدموية وهي خلايا تساعد الدم في التجلط <em>(نقص الصفائح الدموية) </em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; قص في عدد خلايا الدم البيضاء <em>(قلة الكريات البيض)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; قيم مرتفعة/غير طبيعية في اختبار وظائف الكبد</p><p>&nbsp;</p><p>الآثار الجانبية النادرة</p><p>قد تصيب <strong>حتى</strong> <strong>شخص واحد من كل </strong><strong>1000</strong><strong> شخص:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; العدوى</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات الحساسية (انظر أيضًا &quot;تفاعلات الحساسية الشديدة&quot; في جزء سابق من القسم 4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات فرط الحساسية التي يسببها الدواء، والتي تشمل الحمى والطفح الجلدي ونتائج فحوصات الدم غير الطبيعية (انظر التفاعلات الدوائية مع فرط الحمضات والأعراض الجهازية (DRESS) سابقًا في القسم 4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; الانتحار، اضطرابات في الشخصية (مشاكل سلوكية)، تفكير غير طبيعي</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات عضلية لا يمكن السيطرة عليها تؤثر على العينين والرأس والعنق والجسم، وحركات لا يمكن التحكم فيها، وفرط النشاط (فرط نشاط غير معتاد)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكبد، الالتهاب الكبدي</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; حمامي عديدة الأشكال، متلازمة ستيفنز جونسون، انحلال البشرة السُمي (انظر &quot;&rlm;‫تفاعلات البشرة الخطير&quot; سابقًا في القسم 4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; إصابة الكلى الحادة (انظر &quot;التراجع المفاجئ في وظائف الكلى.&quot; سابقًا في القسم 4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; انحلال الربيدات (انحلال النسيج العضلي) ويصاحبه زيادة في فوسفوكيناز الكرياتين في الدم. هناك انتشار أعلى بكثير في المرضى اليابانيين مقارنةً بالمرضى غير اليابانيين.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; عرجة أو صعوبة في المشي.</p><p>&nbsp;</p><p>الآثار الجانبية النادرة التي قد تظهر في فحوصات الدم هي:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; نقص في عدد جميع أنواع خلايا الدم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في مستوى الصوديوم في الدم</p><p><strong>أبلغ الطبيب أو الصيدلاني</strong> في حالة تفاقم أي من الأعراض الجانبية الموضحة هنا أو <strong>إذا أصبحت مزعجة</strong>، أو إذا لاحظت أية أعراض جانبية غير مبيَّنة في هذه النشرة.</p><p>&nbsp;</p><p><strong>للإبلاغ عن أي آثار جانبية:</strong></p><p><strong><em>المملكة العربية السعودية</em></strong></p><p><strong>- المركز القومي للتيقظ والسلامة الدوائية (</strong><strong>NPC</strong><strong>)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس: 7662-205-11-966 +</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية. هاتف: 2038222-11-966+ تحويلة: 2317-2356-2353-2340</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www.sfda.gov.sa/npc</p><p><strong>- جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 6536666-12-966+</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جوال: -56-904-9882966+</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: saudi.safety@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://gskpro.com/en-sa/</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ص.ب. 55850، جدة 21544، المملكة العربية السعودية.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ الدواء بعيدًا عن متناول ومرأى الأطفال.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم كيبرا بعد انتهاء تاريخ الصلاحية المدون على العبوة بعد كلمة &quot;Exp&quot;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ كيبرا في درجات حرارة أقل من 30 درجة مئوية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في العبوة الأصلية لحمايته من الضوء</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك الطبيب بضرورة التوقف عن تناول كيبرا، فمن الضروري إعادة ما تبقى منه إلى الصيدلي.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عدم التخلّص من الأدوية بإلقائها في مياه الصرف أو المخلفات المنزلية. يجب استشارة الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. من شأن هذه الإجراءات أن تساعد على حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي ليـﭭـيتيراسيتام.</p><p><strong><em>كيـﭙـرا</em></strong><em> 250 ملجم: </em>يحتوي كل <em>قرص</em> على 250 ملجم ليـﭭـيتيراسيتام.</p><p><strong><em>كيـﭙـرا</em></strong><em> 500 ملجم: </em>يحتوي كل <em>قرص</em> على 500 ملجم ليـﭭـيتيراسيتام.</p><p><strong><em>كيـﭙـرا</em></strong><em> 1000 ملجم: </em>يحتوي كل <em>قرص</em> على 1000 ملجم ليـﭭـيتيراسيتام.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكونات أخرى غير فعالة:</p><p>&nbsp;&nbsp;&nbsp; <strong>باطن القرص: </strong>كروسكارميلوز الصوديوم، ماكروجول 6000، سيليكا غروية لامائية، ستيارات الماغنسيوم</p><p><strong>الكسوة الغشائية:</strong></p><p><strong><em>كيـﭙـرا 250 ملجم أقراص</em></strong></p><p>أوپادري 85F20694: كحول متعدد الـﭭـاينيل متحلل جزئياً بالماء، ثاني أكسيد التيتانيوم (E171)، ماكروجول 3350، تالك، صبغ الألومينيوم القِرْمِزُي النِّيلِيّ (E132).</p><p><strong><em>كيـﭙـرا 500 ملجم أقراص</em></strong></p><p>أوپادري 85F32004: كحول متعدد الـﭭـاينيل متحلل جزئياً بالماء، ثاني أكسيد التيتانيوم (E171)، ماكروجول 3350، تالك، أكسيد الحديد (E172).</p><p><strong><em>كيـﭙـرا 1000 ملجم أقراص</em></strong></p><p>أوپادري 85F18422: كحول متعدد الـﭭـاينيل متحلل جزئياً بالماء، ثاني أكسيد التيتانيوم (E171)، ماكروجول 3350، تالك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            أقراص كيـﭙـرا 250 ملجم 
تكون زرقاء، مستطيلة الشكل، قابلة للتجزئة، ومنقوش على أحد وجهيها الكود "ucb" و"250". الخط الموجود على القرص هو فقط لتسهيل كسر القرص لأغراض البلع وليس لتقسيمها الى جرعات متساوية.

أقراص كيـﭙـرا 500 ملجم 
تكون صفراء، مستطيلة الشكل، قابلة للتجزئة، ومنقوش على أحد وجهيها الكود "ucb" و"500". الخط الموجود على القرص هو فقط لتسهيل كسر القرص لأغراض البلع وليس لتقسيمها الى جرعات متساوية.

أقراص كيـﭙـرا 1000 ملجم 
تكون بيضاء، مستطيلة الشكل، قابلة للتجزئة، ومنقوش على أحد وجهيها الكود "ucb" و"1000". الخط الموجود على القرص هو فقط لتسهيل كسر القرص لأغراض البلع وليس لتقسيمها الى جرعات متساوية.

العبوة: شرائط فقاعية مصنوعة من الألومينيوم/ كلوريد متعدد الـﭭـاينيل (PVC) داخل علب كرتونية تحتوي على 10، 20، 30، 50، 60، 100، و200 (2 × 100) قرصاً مغلفاً بكسوة غشائية.


قد لا تتوفر جميع أحجام العبوات في السوق.
كيبرا هو علامة تجارية مسجلة لمجموعة شركات جلاكسو سميث كلاين 
© مجموعة شركات جلاكسو سميث كلاين، جميع الحقوق محفوظة.
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>صاحبة رخصة التسويق</strong></p><p>شركة جلاكسو العربية السعودية المحدودة ، جدة، المملكة العربية السعودية</p><p>العنوان: ص. ب. 22617 جدة 21416 &ndash; المملكة العربية السعودية.</p><p>* شركة تنتمي إلى مجموعة شركات جلاكسو سميث كلاين.</p><p>&nbsp;</p><p><strong>تصنيع:</strong></p><p>يو سي بي فارما، برين-لاليود. بلجيكا</p><p><strong>تعبئة: </strong></p><p>جلاكسو المملكة العربية السعودية المحدودة *، جدة، المملكة العربية السعودية.</p><p>&nbsp;</p><p><strong>للإستفسار عن أي معلومات عن هذا المستحضر الدوائي، يرجى الإتصال بالأرقام التالية:</strong></p><p>جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 6536666-12-966+</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جوال: -56-904-9882966+</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://gskpro.com/en-sa/</p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ص.ب. 55850، جدة 21544، المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم الإصدار: NCDS09
تاريخ الإصدار: 17 سبتمبر 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levetiracetam, 500 mg, film-coated tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 500 mg of levetiracetam.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Yellow, oblong film-coated tablet scored and debossed with the code ucb and 500 on one side.
The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Levetiracetam is indicated as monotherapy in the treatment of:</u></p><ul><li>partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.</li></ul><p><u>Levetiracetam is indicated as adjunctive therapy in the treatment of:</u></p><ul><li>partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy,</li><li>myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy,</li><li>primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The film-coated tablets must be taken orally, swallowed with a sufficient quantity of liquid and may be taken with or without food. After oral administration the bitter taste of levetiracetam may be experienced. The daily dose is administered in two equally divided doses.</p><p><strong>Route of Administration</strong></p><p>For oral use.</p><p>Adults</p><p><strong>Monotherapy</strong></p><p><em><u>Adults and adolescents from 16 years of age</u></em></p><p>The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily.</p><p><strong>Add-on therapy</strong></p><p><em><u>Adults (<!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="GREATER-THAN OR EQUAL TO (8805)" style='width:9pt;height:9pt;
 visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/zaa99730/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title="GREATER-THAN OR EQUAL TO (8805)"/>
</v:shape><![endif]--></u></em>&ge;<em><u>18 years) and adolescents (12 to 17 years) weighing 50 kg or more</u></em></p><p>The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment.</p><p>Depending upon the clinical response and tolerability, the daily dose can be increased up to 1500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks.</p><p>Children</p><p>The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose.</p><p>The tablet formulation is not adapted for use in infants and children under the age of 6 years. Levetiracetam oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases levetiracetam oral solution should be used.</p><p><strong>Monotherapy</strong></p><p>The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.</p><p>There are no data available.</p><p><strong>Add-on therapy</strong></p><p><em><u>Add-on therapy for infants aged from 6 to 23 months, children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg</u></em></p><p>Levetiracetam oral solution is the preferred formulation for use in infants and children under the age of 6 years.</p><p>For children 6 years and above, levetiracetam oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.</p><p>The initial therapeutic dose is 10 mg/kg twice daily.</p><p>Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used.</p><p>Dose in children 50 kg or greater is the same as in adults.</p><p><strong>Elderly</strong></p><p>Adjustment of the dose is recommended in elderly patients with compromised renal function.</p><p><strong>Renal impairment</strong></p><p>The daily dose must be individualised according to renal function <em>(see Section Warnings and Precautions).</em></p><p>For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient&#39;s creatinine clearance (CLcr) in ml/min is needed. The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighing 50 kg or more, using the following formula:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [140- age (years)] x weight (kg)</p><p>CLcr (ml/min)= -------------------------------------------- (x 0.85 for women)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 72 x serum creatinine (mg/dl)</p><p>Then CLcr is adjusted for body surface area (BSA) as follows:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLcr (ml/min)</p><p>CLcr (ml/min/1.73 m<sup>2</sup>)= -------------------------- x 1.73</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BSA subject (m<sup>2</sup>)</p><p><u>Dosing adjustment for adult and adolescent patients weighing more than 50kg with impaired renal function</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:595px"><tbody><tr><td style="vertical-align:top"><p><strong>Group</strong></p></td><td style="vertical-align:top"><p><strong>Creatinine clearance&nbsp; </strong></p><p><strong>(ml/min/1.73m<sup>2</sup>)</strong></p></td><td style="vertical-align:top"><p><strong>Dosage and frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Normal</p></td><td style="vertical-align:top"><p>&gt; 80</p></td><td style="vertical-align:top"><p>500 to 1500 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>50-79</p></td><td style="vertical-align:top"><p>500 to 1000 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>30-49</p></td><td style="vertical-align:top"><p>250 to 750 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>&lt; 30</p></td><td style="vertical-align:top"><p>250 to 500 mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>End-stage renal disease patients undergoing dialysis<sup>(1)</sup>.</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>500 to 1000 mg once daily <sup>(2)</sup></p></td></tr></tbody></table><p><sup>(1)</sup> A 750 mg loading dose is recommended on the first day of treatment with levetiracetam.</p><p><sup>(2)</sup> Following dialysis, a 250 to 500 mg supplemental dose is recommended.</p><p>For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function.</p><p>This recommendation is based on a study in adult renally impaired patients.</p><p>The CLcr in ml/min/1.73 m<sup>2 </sup>may be estimated from serum creatinine (mg/dl) determination using, for young adolescents and children using the following formula (Schwartz formula):</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Height (cm) x ks</p><p>CLcr (ml/min/1.73 m<sup>2</sup>)= ---------------------------------------</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serum Creatinine (mg/dl)</p><p>ks= 0.45 in Term infants to 1 year old; ks= 0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in adolescent male</p><p>Dosing adjustment for infants, children and adolescents patients weighing less than 50 kg with impaired renal function</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Group</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Creatinine clearance (ml/min/1.73m<sup>2</sup>)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Dosage and frequency </strong><sup>(1)</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infants 1 to less than 6 months</strong></p></td><td style="vertical-align:top"><p><strong>Infants 6 to 23 months, children and adolescents weighing less than 50 kg</strong></p></td></tr><tr><td style="vertical-align:top"><p>Normal</p></td><td style="vertical-align:top"><p>&gt; 80</p></td><td style="vertical-align:top"><p>7 to 21 mg/kg (0.07 to 0.21 ml/kg) twice daily</p></td><td style="vertical-align:top"><p>10 to 30 mg/kg (0.10 to 0.30 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Mild</p></td><td style="vertical-align:top"><p>50-79</p></td><td style="vertical-align:top"><p>7 to 14 mg/kg (0.07 to 0.14 ml/kg) twice daily</p></td><td style="vertical-align:top"><p>10 to 20 mg/kg (0.10 to 0.20 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Moderate</p></td><td style="vertical-align:top"><p>30-49</p></td><td style="vertical-align:top"><p>3.5 to 10.5 mg/kg (0.035 to 0.105 ml/kg) twice daily</p></td><td style="vertical-align:top"><p>5 to 15 mg/kg (0.05 to 0.15 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Severe</p></td><td style="vertical-align:top"><p>&lt; 30</p></td><td style="vertical-align:top"><p>3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) twice daily</p></td><td style="vertical-align:top"><p>5 to 10 mg/kg (0.05 to 0.10 ml/kg) twice daily</p></td></tr><tr><td style="vertical-align:top"><p>End-stage renal disease patients undergoing dialysis</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>7 to 14 mg/kg (0.07 to 0.14 ml/kg) once daily <sup>(2) (4)</sup></p></td><td style="vertical-align:top"><p>10 to 20 mg/kg (0.10 to 0.20 ml/kg) once daily <sup>(3) (5)</sup></p></td></tr></tbody></table><p>&nbsp;</p><p><sup>(1)</sup> Levetiracetam oral solution should be used for doses under 250 mg, for doses not multiple of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets.</p><p><sup>(2)</sup> A 10.5 mg/kg (0.105 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.</p><p><sup>(3)</sup> A 15 mg/kg (0.15 ml/kg) loading dose is recommended on the first day of treatment with levetiracetam.</p><p><sup>(4)</sup> Following dialysis, a 3.5 to 7 mg/kg (0.035 to 0.07 ml/kg) supplemental dose is recommended.</p><p><sup>(5)</sup> Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 ml/kg) supplemental dose is recommended.</p><p><strong>Hepatic impairment</strong></p><p>No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. Therefore a 50 % reduction of the daily maintenance dose is recommended when the creatinine clearance is &lt; 60 ml/min/1.73 m<sup>2</sup>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levetiracetam is contraindicated in:
•	hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Discontinuation</em></p><p>If levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months,&nbsp; children and adolescents weighing less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants less than 6 months: dose decrease should not exceed 7 mg/kg twice daily every two weeks).</p><p><em>Renal or hepatic impairment</em></p><p>The administration of levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection.</p><p><em>Acute kidney injury </em></p><p>The use of levetiracetam has been very rarely associated with acute kidney injury, with a time to onset ranging from a few days to several months.</p><p><em>Blood cell counts </em></p><p>Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders <em>(see Section Adverse Reactions)</em>.</p><p><em>Depression and/or suicidal ideation</em></p><p>Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known.</p><p>Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.</p><p><em>Paediatric population</em></p><p>The tablet formulation is not adapted for use in infants and children under the age of<br />6 years.</p><p>Available data in children did not suggest impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Antiepileptic medicinal products</em></p><p>Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam.</p><p>As in adults, there is no evidence of clinically significant medicinal product interactions in paediatric patients receiving up to 60 mg/kg/day levetiracetam.</p><p>A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. However, data suggested a 20 % higher levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. Dose adjustment is not required.</p><p><em>Probenecid</em></p><p>Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.</p><p><em>Methotrexate</em></p><p>Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.</p><p><em>Oral contraceptives, digoxin and warfarin</em></p><p>Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of levetiracetam.</p><p><em>Laxatives </em></p><p>There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.</p><p><em>Food and alcohol</em></p><p>The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced.</p><p>No data on the interaction of levetiracetam with alcohol are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility</strong></p><p>No impact on fertility was detected in animal studies. No clinical data are available, potential risk for human is unknown.</p><p>Women of childbearing potential</p><p>Specialist advice should be given to women who are of childbearing potential. Treatment with levetiracetam should be reviewed when a woman is planning to become pregnant. As with all antiepileptic medicines, sudden discontinuation of levetiracetam should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. Monotherapy should be preferred whenever possible because therapy with multiple antiepileptic medicines AEDs could be associated with a higher risk of congenital malformations than monotherapy, depending on the associated antiepileptics.</p><p><strong>Pregnancy</strong></p><p>A large amount of postmarketing data on pregnant women exposed to levetiracetam monotherapy (more than 1800, among which in more than 1500 exposure occurred during the first trimester) do not suggest an increase in the risk for major congenital malformations. Only limited evidence is available on the neurodevelopment of children exposed to levetiracetam monotherapy in utero. However, current epidemiological studies (on about 100 children) do not suggest an increased risk of neurodevelopmental disorders or delays.</p><p>Levetiracetam can be used during pregnancy, if after careful assessment it is considered clinically needed. In such case, the lowest effective dose is recommended.</p><p>Physiological changes during pregnancy may affect levetiracetam concentration. Decrease in levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy). Appropriate clinical management of pregnant women treated with levetiracetam should be ensured.</p><p><strong>Lactation</strong></p><p>Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended.</p><p>However, if levetiracetam treatment is needed during breastfeeding, the benefit/ risk of the treatment should be weighed considering the importance of breastfeeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levetiracetam has minor or moderate influence on the ability to drive and use machines.</p><p>Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks, e.g. driving vehicles or operating machinery. Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Clinical Trial Data and Post Marketing Data</strong></p><p><em>Summary of the safety profile</em></p><p>The adverse event profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam. These data are supplemented with the use of levetiracetam in corresponding open-label extension studies, as well as post-marketing experience. The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness. The safety profile of levetiracetam is generally similar across age groups (adult and paediatric patients) and across the approved epilepsy indications.</p><p>Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency.</p><p>Frequencies are defined as:</p><p>Very common &ge;1/10</p><p>Common &ge;1/100 to &lt;1/10</p><p>Uncommon &ge;1/1000 to &lt;1/100</p><p>Rare &ge;1/10000 to &lt;1/1000</p><p>Very rare &lt;1/10000</p><p>Not known (cannot be estimated from the available data).</p><p><em>Infections and infestations</em></p><p><em>Very common: </em>nasopharyngitis</p><p><em>Rare:</em> infection</p><p><em>Blood and lymphatic system disorders</em></p><p><em>Uncommon: </em>thrombocytopenia, leukopenia</p><p><em>Rare: </em>pancytopenia, neutropenia, agranulocytosis</p><p><em>Immune system disorders</em></p><p><em>Rare: </em>drug reaction with eosinophilia and systemic symptoms (DRESS), hypersensitivity (including angioedema and anaphylaxis)</p><p><em>Metabolism and nutrition disorders</em></p><p><em>Common: </em>anorexia</p><p><em>Uncommon: </em>weight decreased, weight increase</p><p><em>Rare</em>: hyponatraemia</p><p><em>Psychiatric disorders</em></p><p><em>Common: </em>depression, hostility/ aggression, anxiety, insomnia, nervousness/ irritability</p><p><em>Uncommon: </em>suicide attempt, suicidal ideation, psychotic disorder, abnormal behaviour, hallucination, anger, confusional state, panic attack, affect lability/ mood swings, agitation</p><p><em>Rare:</em> completed suicide, personality disorder, thinking abnormal</p><p><em>Nervous system disorders</em></p><p><em>Very common: </em>somnolence, headache</p><p><em>Common: </em>convulsion, balance disorder, dizziness, lethargy, tremor</p><p><em>Uncommon</em>: amnesia, memory impairment, coordination abnormal/ ataxia, paraesthesia, disturbance in attention</p><p><em>Rare: </em>choreoathetosis, dyskinesia, hyperkinesia, gait disturbance</p><p><em>Eye disorders</em></p><p><em>Uncommon: </em>diplopia, vision blurred</p><p><em>Ear and labyrinth disorders</em></p><p><em>Common:</em> vertigo</p><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p><em>Common: </em>cough</p><p><em>Gastrointestinal disorders</em></p><p><em>Common: </em>abdominal pain, diarrhoea, dyspepsia, vomiting, nausea</p><p><em>Rare: </em>pancreatitis</p><p><em>Hepatobiliary disorders</em></p><p><em>Uncommon: </em>liver function test abnormal</p><p><em>Rare: </em>hepatic failure, hepatitis</p><p><em>Renal and urinary disorders</em></p><p><em>Rare:</em> acute kidney injury</p><p><em>Skin and subcutaneous tissue disorders</em></p><p><em>Common: </em>rash</p><p><em>Uncommon: </em>alopecia, eczema, pruritus,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><em>Rare: </em>toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme</p><p><em>Musculoskeletal and connective tissue disorders</em></p><p><em>Uncommon: </em>muscular weakness, myalgia</p><p><em>Rare:</em> rhabdomyolysis and blood creatine phosphokinase increased*</p><p><em>General disorders and administration site conditions</em></p><p><em>Common: </em>asthenia/fatigue</p><p><em>Injury, poisoning and procedural complications</em></p><p><em>Uncommon:</em> injury</p><p>* Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.</p><p>Cases of encephalopathy have been rarely observed after levetiracetam administration. These undesirable effects generally occurred at the beginning of the treatment (few days to a few months) and were reversible after treatment discontinuation.</p><p><em>Description of selected adverse reactions</em></p><p>The risk of anorexia is higher when levetiracetamis coadministered with topiramate.</p><p>In several cases of alopecia, recovery was observed when levetiracetam was discontinued.</p><p>Bone marrow suppression was identified in some of the cases of pancytopenia.</p><p><em>Paediatric population</em></p><p>In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with levetiracetam in placebo controlled and open label extension studies. Sixty of these patients were treated with levetiracetam in placebo-controlled studies. In patients aged 4-16 years, a total of 645 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. 233 of these patients were treated with levetiracetam in placebo-controlled studies. In both these paediatric age ranges, these data are supplemented with the post-marketing experience of the use of levetiracetam.</p><p>In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety study. No new safety concerns for levetiracetam were identified for infants less than 12 months of age with epilepsy.</p><p>The adverse event profile of levetiracetam is generally similar across age groups and across the approved epilepsy indications. Safety results in paediatric patients in placebo-controlled clinical studies were consistent with the safety profile of levetiracetam in adults except for behavioural and psychiatric adverse reactions which were more common in children than in adults. In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile. In infants and children aged 1 month to less than 4 years, irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more frequently than in other age groups or in the overall safety profile.</p><p>A double-blind, placebo-controlled paediatric safety study with a non-inferiority design has assessed the cognitive and neuropsychological effects of levetiracetam in children 4 to 16 years of age with partial onset seizures. It was concluded that levetiracetam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population. Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardised and systematic way using a validated instrument (CBCL &ndash; Achenbach Child Behavior Checklist). However subjects, who took levetiracetam in the long term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behaviour were not worse than baseline.</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Fax: +966-11-205-7662</li><li>Call NPC at +966-11-2038222, Ext: 2317-2356-2340</li><li>Reporting hotline: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: sa.aermi-saudi@gsk.com</li><li>website: https://healthksa.gsk.com/</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms and signs</strong></p><p>Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses.</p><p><strong>Treatment</strong></p><p>There is no specific antidote for levetiracetam. Treatment of an overdose will be symptomatic and may include haemodialysis. The dialyser extraction efficiency is 60 % for levetiracetam and 74 % for the primary metabolite.</p><p>Further management should be as clinically indicated or as recommended by the national poisons centre, where available.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group</strong></p><p>Antiepileptics; Other Antiepileptics</p><p><strong>ATC Code</strong></p><p>N03AX14</p><p><strong>Mechanism of Action</strong></p><p>The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of &alpha;-ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.</p><p>The mechanism of action of levetiracetam still remains to be fully elucidated. <em>In vitro</em> and <em>in vivo</em> experiments suggest that levetiracetam does not alter basic cell characteristics and normal neurotransmission.</p><p><em>In vitro</em> studies show that levetiracetam affects intraneuronal Ca<sup>2+</sup> levels by partial inhibition of N-type Ca<sup>2+</sup> currents and by reducing the release of Ca<sup>2+</sup> from intraneuronal stores. In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and &beta;-carbolines. Furthermore, levetiracetam has been shown in <em>in vitro</em> studies to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.</p><p><strong>Pharmacodynamic effects</strong></p><p>Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalised seizures without having a pro-convulsant effect. The primary metabolite is inactive.</p><p>In man, an activity in both partial and generalised epilepsy conditions (epileptiform discharge/ photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of levetiracetam.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levetiracetam is a highly soluble and permeable compound. The pharmacokinetic profile is linear with low intra- and intersubject variability. There is no modification of the clearance after repeated administration. The time independent pharmacokinetic profile of levetiracetam was also confirmed following 1500 mg intravenous infusion for 4 days with twice daily dosing dosing.</p><p>There is no evidence for any relevant gender, race or circadian variability. The pharmacokinetic profile is comparable in healthy volunteers and in patients with epilepsy.</p><p>Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg/kg bodyweight. Therefore there is no need for plasma level monitoring of levetiracetam.</p><p>A significant correlation between saliva and plasma concentrations has been shown in adults and children (ratio of saliva/plasma concentrations ranged from 1 to 1.7 for oral tablet formulation and after 4 hours post-dose for oral solution formulation).</p><p>The pharmacokinetic profile has been characterized following oral administration. A single dose of 1500 mg levetiracetam diluted in 100 ml of a compatible diluent and infused intravenously over 15 minutes is bioequivalent to 1500 mg levetiracetam</p><p>oral intake, given as three 500 mg tablets.</p><p>The intravenous administration of doses up to 4000 mg diluted in 100 ml of 0.9 % sodium chloride infused over 15 minutes and doses up to 2500 mg diluted in 100 ml of 0.9 % sodium chloride infused over 5 minutes was evaluated. The pharmacokinetic and safety profiles did not identify any safety concerns.</p><p><strong>Absorption</strong></p><p>Levetiracetam is rapidly absorbed after oral administration. Oral absolute bioavailability is close to 100 %.</p><p>Peak plasma concentrations (C<sub>max</sub>) are achieved at 1.3 hours after dosing. Steady-state is achieved after two days of a twice daily administration schedule.</p><p>Peak concentrations (C<sub>max</sub>) are typically 31 and 43 &mu;g/ml following a single 1,000 mg dose and repeated 1,000 mg twice daily dose, respectively.</p><p>The extent of absorption is dose-independent and is not altered by food.</p><p><strong>Distribution</strong></p><p>No tissue distribution data are available in humans.</p><p>Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins (&lt; 10 %). The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume.</p><p>Peak plasma concentration (C<sub>max</sub>) observed in 17 subjects following a single intravenous dose of 1500 mg infused over 15 minutes was 51 &plusmn; 19 &mu;g/mL (arithmetic average &plusmn; standard deviation).</p><p><strong>Metabolism</strong></p><p>Levetiracetam is not extensively metabolised in humans. The major metabolic pathway (24 % of the dose) is an enzymatic hydrolysis of the acetamide group. Production of the primary metabolite, ucb L057, is not supported by liver cytochrome P450 isoforms. Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. The metabolite ucb L057 is pharmacologically inactive.</p><p>Two minor metabolites were also identified. One was obtained by hydroxylation of the pyrrolidone ring (1.6 % of the dose) and the other one by opening of the pyrrolidone ring (0.9 % of the dose).</p><p>Other unidentified components accounted only for 0.6 % of the dose.</p><p>No enantiomeric interconversion was evidenced in vivo for either levetiracetam or its primary metabolite.</p><p><em>In vitro</em>, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P<sub>450</sub> isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 and UGT1A6) and epoxide hydroxylase activities. In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid.</p><p>In human hepatocytes in culture, levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1. Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The in vitro data and in vivo interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected in vivo. Therefore, the interaction of levetiracetam with other substances, or vice versa, is unlikely.</p><p><strong>Elimination</strong></p><p>The plasma half-life in adults was 7&plusmn;1 hours and did not vary either with dose, route of administration or repeated administration. The mean total body clearance was 0.96 ml/min/kg.</p><p>The major route of excretion was via urine, accounting for a mean 95 % of the dose (approximately 93 % of the dose was excreted within 48 hours). Excretion via faeces accounted for only 0.3 % of the dose.</p><p>The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours.</p><p>The renal clearance of levetiracetam and ucb L057 is 0.6 and 4.2 ml/min/kg respectively indicating that levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration. Levetiracetam elimination is correlated to creatinine clearance.</p><p><strong>Special patient populations</strong></p><p><strong>Children</strong></p><p><em>Children (4 to 12 years)</em></p><p>Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6.0 hours. The apparent body weight adjusted clearance was approximately 30 % higher than in epileptic adults.</p><p>Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. Linear and dose proportional increases were observed for peak plasma concentrations and area under the curve. The elimination half-life was approximately 5 hours. The apparent body clearance was 1.1 ml/min/kg.</p><p><em>Infants and children (1 month to 4 years)</em></p><p>Following single dose administration (20 mg/kg) of a 100 mg/ml oral solution to epileptic children (1 month to 4 years), levetiracetam was rapidly absorbed and peak plasma concentrations were observed approximately 1 hour after dosing. The pharmacokinetic results indicated that half-life was shorter (5.3 h) than for adults (7.2 h) and apparent clearance was faster (1.5 ml/min/kg) than for adults (0.96 ml/min/kg).</p><p>In the population pharmacokinetic analysis conducted in patients from 1 month to 16 years of age, body weight was significantly correlated to apparent clearance (clearance increased with an increase in body weight) and apparent volume of distribution. Age also had an influence on both parameters. This effect was pronounced for the younger infants, and subsided as age increased, to become negligible around 4 years of age.</p><p>In both population pharmacokinetic analyses, there was about a 20 % increase of apparent clearance of levetiracetam when it was co-administered with an enzyme inducing antiepileptic medicinal product.</p><p>Elderly</p><p>In the elderly, the half-life is increased by about 40 % (10 to 11 hours). This is related to the decrease in renal function in this population.</p><p><strong>Renal impairment</strong></p><p>The apparent body clearance of both levetiracetam and of its primary metabolite is correlated to the creatinine clearance. It is therefore recommended to adjust the maintenance daily dose of levetiracetam, based on creatinine clearance in patients with moderate and severe renal impairment.</p><p>In anuric end-stage renal disease adult subjects the half-life was approximately 25 and 3.1 hours during interdialytic and intradialytic periods, respectively.</p><p>The fractional removal of levetiracetam was 51 % during a typical 4-hour dialysis session.</p><p><strong>Hepatic impairment</strong></p><p>In subjects with mild and moderate hepatic impairment, there was no relevant modification of the clearance of levetiracetam.</p><p>In most subjects with severe hepatic impairment, the clearance of levetiracetam was reduced by more than 50 % due to a concomitant renal impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not relevant for this product.</p><p><strong>Non-clinical information</strong></p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenicity.</p><p>Adverse effects not observed in clinical studies but seen in the rat and to a lesser extent in the mouse at exposure levels similar to human exposure levels and with possible relevance for clinical use were liver changes, indicating an adaptive response such as increased weight and centrilobular hypertrophy, fatty infiltration and increased liver enzymes in plasma.</p><p>No adverse effects on male or female fertility or reproduction performance were observed in rats at doses up to 1800 mg/kg/day (x 6 the MRHD on a mg/m<sup>2</sup> or exposure basis) in parents and F1 generation.</p><p>Two embryo-foetal development (EFD) studies were performed in rats at 400, 1200 and 3600 mg/kg/day. At 3600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in foetal weight associated with a marginal increase in skeletal variations/minor anomalies. There was no effect on embryomortality and no increased incidence of malformations. The NOAEL (No Observed Adverse Effect Level) was 3600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m<sup>2</sup> basis) and 1200 mg/kg/day for foetuses.</p><p>Four embryo-foetal development studies were performed in rabbits covering doses of 200, 600, 800, 1200 and 1800 mg/kg/day. The dose level of 1800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of foetuses with cardiovascular/skeletal anomalies. The NOAEL was<br />&lt;200 mg/kg/day for the dams and 200 mg/kg/day for the foetuses (equal to the MRHD on a mg/m<sup>2</sup> basis).</p><p>A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1800 mg/kg/day. The NOAEL was &ge; 1800 mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning (x 6 the MRHD on a mg/m<sup>2 </sup>basis).</p><p>Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1800 mg/kg/day (x 6&ndash;17 the MRHD on a mg/m<sup>2</sup> basis).</p><p><em>Environmental Risk Assessment (ERA)</em></p><p>The use of levetiracetam in accordance with the product information is not likely to result in an unacceptable environmental impact <em>(see Section </em><em>Incompatibilities and Use and Handling).</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Tablet core: </strong>croscarmellose sodium, macrogol 6000, silica colloidal anhydrous, magnesium stearate.</p><p><strong>Film-coating: </strong>Opadry 85F32004: Polyvinyl alcohol-part.hydrolyzed, Titanium dioxide (E171), Macrogol 3350, Talc, Iron oxide (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                As indicated on the outer pack. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/PVC blisters placed into cardboard boxes containing 10, 20, 30, 50, 60, 100 and 200 (2 x 100) film-coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Not all packs are marketed in every country.</p><p>&nbsp;</p><p>Keppra is a registered trademark of the GlaxoSmithKline group of companies</p><p>&copy; 2019 GlaxoSmithKline group of companies. All rights reserved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder 
Glaxo Saudi Arabia Ltd.* Jeddah, KSA.
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia.
*member of GlaxoSmithKline group of companies

Manufactured by 
UCB PHARMA SA, BRAINE-L’ALLEUD. BELGIUM 

Packed by: 
Glaxo Saudi Arabia Ltd*, Jeddah, KSA
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: NCDS 09
Version date: 17 September 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>